Literature DB >> 22928868

Anxiolytic- and panicolytic-like effects of Neuropeptide S in the mouse elevated T-maze.

Alice Pulga1, Chiara Ruzza, Anna Rizzi, Remo Guerrini, Girolamo Calo.   

Abstract

Neuropeptide S (NPS) regulates various biological functions by selectively activating the NPS receptor (NPSR). Recently, epidemiological studies revealed an association between NPSR single nucleotide polymorphisms and susceptibility to panic disorders. Here we investigated the effects of NPS in mice subjected to the elevated T maze (ETM), an assay which has been proposed to model anxiety and panic. Diazepam [1 mg/kg, intraperitoneally (i.p.)] elicited clear anxiolytic effects reducing the latency to emerge from the closed to the open (CO) arm without modifying the latencies from the open to the closed (OC) arm. By contrast, chronic fluoxetine (10 mg/kg i.p., once a day for 21 days) selectively increased OC latency, suggesting a panicolytic-like effect. NPS given intracerebroventricularly at 0.001-1 nmol elicited both anxiolytic- and panicolytic-like effects. However, although the NPS anxiolytic dose-response curve displayed the classical sigmoidal shape, the dose-response curve of the putative panicolytic-like effect was bell shaped with peak effect at 0.01 nmol. The behaviour of wild-type [NPSR(+/+)] and receptor knock out [NPSR(-/-)] mice in the ETM task was superimposable. NPS at 0.01 nmol elicited anxiolytic- and panicolytic-like effects in NPSR(+/+) but not in NPSR(-/-) mice. In conclusion, this study demonstrated that NPS, via selective activation of the NPSR, promotes both anxiolytic- and panicolytic-like actions in the mouse ETM.
© 2012 The Authors. European Journal of Neuroscience © 2012 Federation of European Neuroscience Societies and Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22928868     DOI: 10.1111/j.1460-9568.2012.08265.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  12 in total

Review 1.  Candidate genes in panic disorder: meta-analyses of 23 common variants in major anxiogenic pathways.

Authors:  A S Howe; H N Buttenschøn; A Bani-Fatemi; E Maron; T Otowa; A Erhardt; E B Binder; N O Gregersen; O Mors; D P Woldbye; K Domschke; A Reif; J Shlik; S Kõks; Y Kawamura; A Miyashita; R Kuwano; K Tokunaga; H Tanii; J W Smoller; T Sasaki; D Koszycki; V De Luca
Journal:  Mol Psychiatry       Date:  2015-09-22       Impact factor: 15.992

Review 2.  Nuance and behavioral cogency: How the Visible Burrow System inspired the Stress-Alternatives Model and conceptualization of the continuum of anxiety.

Authors:  James M Robertson; Melissa A Prince; Justin K Achua; Russ E Carpenter; David H Arendt; Justin P Smith; Torrie L Summers; Tangi R Summers; Cliff H Summers
Journal:  Physiol Behav       Date:  2015-07-01

3.  Neuroleptics Affect Neuropeptide S and NPSR mRNA Levels in the Rat Brain.

Authors:  Artur Pałasz; Ewa Rojczyk
Journal:  J Mol Neurosci       Date:  2015-07-31       Impact factor: 3.444

Review 4.  Amygdala, neuropeptides, and chronic pain-related affective behaviors.

Authors:  Volker Neugebauer; Mariacristina Mazzitelli; Bryce Cragg; Guangchen Ji; Edita Navratilova; Frank Porreca
Journal:  Neuropharmacology       Date:  2020-03-15       Impact factor: 5.250

5.  Intensity of anxiety is modified via complex integrative stress circuitries.

Authors:  Justin P Smith; Melissa A Prince; Justin K Achua; James M Robertson; Raymond T Anderson; Patrick J Ronan; Cliff H Summers
Journal:  Psychoneuroendocrinology       Date:  2015-10-24       Impact factor: 4.905

6.  Derivatives of a new heterocyclic system - pyrano[3,4-c][1,2,4]triazolo[4,3-a]pyridines: synthesis, docking analysis and neurotropic activity.

Authors:  Ervand G Paronikyan; Anthi Petrou; Maria Fesatidou; Athina Geronikaki; Shushanik Sh Dashyan; Suren S Mamyan; Ruzanna G Paronikyan; Ivetta M Nazaryan; Hasmik H Hakopyan
Journal:  Medchemcomm       Date:  2019-06-19       Impact factor: 3.597

Review 7.  Relaxin-3/RXFP3 networks: an emerging target for the treatment of depression and other neuropsychiatric diseases?

Authors:  Craig M Smith; Andrew W Walker; Ihaia T Hosken; Berenice E Chua; Cary Zhang; Mouna Haidar; Andrew L Gundlach
Journal:  Front Pharmacol       Date:  2014-03-21       Impact factor: 5.810

8.  A single-nucleotide polymorphism of human neuropeptide s gene originated from Europe shows decreased bioactivity.

Authors:  Cheng Deng; Ximiao He; Aaron J W Hsueh
Journal:  PLoS One       Date:  2013-12-27       Impact factor: 3.240

9.  In vitro and in vivo pharmacological characterization of a neuropeptide S tetrabranched derivative.

Authors:  Chiara Ruzza; Anna Rizzi; Davide Malfacini; Alice Pulga; Salvatore Pacifico; Severo Salvadori; Claudio Trapella; Rainer K Reinscheid; Girolamo Calo; Remo Guerrini
Journal:  Pharmacol Res Perspect       Date:  2015-01-05

10.  Neuropeptide S- and Neuropeptide S receptor-expressing neuron populations in the human pons.

Authors:  Csaba Adori; Swapnali Barde; Nenad Bogdanovic; Mathias Uhlén; Rainer R Reinscheid; Gabor G Kovacs; Tomas Hökfelt
Journal:  Front Neuroanat       Date:  2015-09-25       Impact factor: 3.856

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.